US Patent

US9527833 — Stable crystal form of tipiracil hydrochloride and crystallization method for the same

Composition of Matter · Assigned to Taiho Pharmaceutical Co Ltd · Expires 2034-06-17 · 8y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a stable crystal form of tipiracil hydrochloride and a method for crystallizing it, characterized by specific powder X-ray diffraction peaks.

USPTO Abstract

An objective of the present invention is to obtain a stable crystal form of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride. The present invention provides a crystal of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride exhibiting characteristic peaks at angles of 11.6°, 17.2°, 17.8°, 23.3°, 27.1°, and 29.3° as a diffraction angle (2θ±0.1°) in powder X-ray diffraction.

Drugs covered by this patent

Patent Metadata

Patent number
US9527833
Jurisdiction
US
Classification
Composition of Matter
Expires
2034-06-17
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Taiho Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.